The ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) on May 22 announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) weekly performance is 0.75%. On last trading day company shares ended up $4.05. Analysts mean target price for the company is $7.00. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) distance from 50-day simple moving average is 13.66%.
Analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $23.10 price target on the stock. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares fell -8.08% in last trading session and ended the day on $22.71. OMED its return on assets is -18.80%. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) quarterly performance is -31.58%.
Insys Therapeutics Inc (NASDAQ:INSY) announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on June 24-25, 2014 at the Westin New York Grand Central. Insys Therapeutics Inc (NASDAQ:INSY) shares moved up 3.28% in last trading session and was closed at $25.85, while trading in range of $23.51-$26.35. Insys Therapeutics Inc (NASDAQ:INSY) year to date performance is 0.15%.
22nd Century Group, Inc. (NYSE MKT:XXII) announced that on June 9, 2014 the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance to the Company for technology that reduces nicotine in tobacco by suppressing expression of the NBB gene by itself and in combination with other nicotine biosynthesis genes.22nd Century Group Inc (NYSEMKT:XXII) ended the last trading day at $3.78. Company weekly volatility is calculated as 8.85% and price to cash ratio as 38.23. 22nd Century Group Inc (NYSEMKT:XXII) showed a positive weekly performance of 20.38%.
Analysts at Jefferies Group cut their price target on shares of Arrowhead Research Corp (NASDAQ:ARWR)from $30.00 to $29.00 in a research note on Wednesday, May 7th. They now have a “buy” rating on the stock. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -13.23%. On last trading day company shares ended up $12.33. Analysts mean target price for the company is $27.90. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average is -3.40%.
Leave a Reply